Jcr pharmaceuticals and acumen pharmaceuticals announce collaboration to develop therapy for alzheimer's disease, enabled by j-brain cargo® technology platform

Hyogo, japan--(business wire)--jcr pharmaceuticals co., ltd. (tse 4552; jcr), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced a joint collaboration, option and license agreement with acumen pharmaceuticals to develop a novel therapeutic candidate for the treatment of alzheimer's disease (ad), enabled by jcr's proprietary blood-brain barrier (bbb)-penetrating technology platform, j-brain cargo®. the collaboration focus.
ABOS Ratings Summary
ABOS Quant Ranking